A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-Na�ve and Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pati
Read time: 1 mins
Last updated:9th Apr 2013
To evaluate the safety of abiraterone acetate with 4 alternative steroid treatment strategies related to symptoms associated with mineralocorticoid excess toxicities (ie, hypokalemia and/or hypertension) during the first 24 weeks of treatment in asymptomatic, chemotherapy-naïve, mCRPC subjects.
|Study start date||2013-04-09|